reglab/housing_qa huggingface dataset:
NJ Rev Stat § 26:2-111.5 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-111.5 - Testing of newborns for certain lysomal storage disorders required.

26:2-111.5 Testing of newborns for certain lysomal storage disorders required.  1. a. All infants born in this State shall be tested for the lysosomal storage disorders known as Krabbe, Pompe, Gaucher, Fabry, and Niemann-Pick diseases within six months following the occurrence of all of the following:  (1) the registration with the federal Food and Drug Administration of the necessary reagents;  (2) the availability of the necessary reagents from the federal Centers for Disease Control and Prevention;  (3) the availability of quality assurance testing methodology for these processes; and  (4) the acquisition by the Department of Health of the equipment necessary to implement the expanded screening tests. b. The Department of Health may charge a reasonable fee for the tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.  L.2011, c.175, s.1; amended 2012, c.17, s.120.
NJ Rev Stat § 26:2-111.6 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-111.6 - Testing of infants for adrenoleukodystrophy.

26:2-111.6 Testing of infants for adrenoleukodystrophy.  1. a. All infants born in this State shall be tested for adrenoleukodystrophy (ALD) beginning six months following the occurrence of all of the following: (1) the development of a reliable test or series of tests for screening newborns for ALD using dried blood spots and quality assurance testing methodology for ALD testing; (2) the availability of quality assurance materials for the ALD test from the federal Centers for Disease Control and Prevention;  (3) the inclusion of newborn screening for ALD in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for ALD; (4) the review by the Department of Health of the proposed test; and (5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory. b. The Department of Health may charge a reasonable fee and any reasonable increase in this fee as necessary, for the test performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health. L.2013, c.90, s.1.
NJ Rev Stat § 26:2-111.7 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-111.7 - "Let Them Be Little Act," screening of newborns for MPSI and MPSII provided.

26:2-111.7 "Let Them Be Little Act," screening of newborns for MPSI and MPSII provided.  1. a. All infants born in this State shall be tested for mucopolysaccharidosis I (MPS I), also known as Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome, beginning six months following the occurrence of all of the following: (1) the development of a reliable test or series of tests for screening newborns for MPS I using dried blood spots and quality assurance testing methodology for Hunter syndrome testing; (2) the availability of quality assurance materials for the MPS I test from the federal Centers for Disease Control and Prevention;  (3) the inclusion of newborn screening for MPS I in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for MPS I; (4) the review by the Department of Health of the proposed test; and (5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory. b. All infants born in this State shall be tested for mucopolysaccharidosis II (MPS II), also called Hunter syndrome, beginning six months following the occurrence of all of the following: (1) the development of a reliable test or series of tests for screening newborns for MPS II using dried blood spots and quality assurance testing methodology for Hunter syndrome testing; (2) the availability of quality assurance materials for the MPS II test from the federal Centers for Disease Control and Prevention;  (3) the inclusion of newborn screening for MPS II in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for MPS II; (4) the review by the Department of Health of the proposed test; and (5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory. c. The Department of Health may charge a reasonable fee and any reasonable increase in this fee as necessary, for the tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health. L.2014, c.44, s.1.
NJ Rev Stat § 26:2-111.8 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-111.8 - Screening of newborn infants for spinal muscular atrophy.

26:2-111.8 Screening of newborn infants for spinal muscular atrophy.  1. a. Each infant born in this State shall be tested for the genetic mutations associated with spinal muscular atrophy. b. The Commissioner of Health shall develop a comprehensive program of follow-up services and procedures in the event a newborn tests positive for one or more genetic markers associated with spinal muscular atrophy, which services and procedures shall include, at a minimum:  (1) genetic counseling for the parents of the newborn concerning the risk that one or both parents is a carrier of the genetic mutation associated with spinal muscular atrophy, and the risk that other children born to the parents may carry the mutation, pass it on to their own offspring, or may be born with spinal muscular atrophy; and  (2) information concerning available treatment options for spinal muscular atrophy. c. The Department of Health may charge a reasonable fee to administer tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health. d. The Commissioner of Health shall adopt rules and regulations, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), necessary to carry out the purposes of this section. L.2019, c.390, s.1.
NJ Rev Stat § 26:2-112 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-112 - Agreements with federal government and public health agencies of other states

26:2-112. Agreements with federal government and public health agencies of other states  The commissioner is authorized to enter into agreements with the Federal Government and public health agencies in other states to achieve greater effectiveness or efficiency in carrying out the provisions of this act. L.1981, c. 357, s. 4.
NJ Rev Stat § 26:2-113 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-113 - Legislative findings and declarations

26:2-113. Legislative findings and declarations  The Legislature finds that the effective identification, diagnosis, care and treatment of persons who have been exposed to diethylstilbestrol, commonly referred to as DES, is of paramount public importance; that DES, a synthetic estrogen-type hormone, was extensively administered between 1940 and 1970 to pregnant women threatened with miscarriage; that, subsequently, a causal relationship was found between DES and an unusual type of cervical and vaginal cancer in the daughters of persons who took the drug during pregnancy; that use of DES during pregnancy has been discontinued as a result of these findings, but that as many as 75,000 persons in New Jersey may have been exposed to the drug during its period of usage. The Legislature further finds that the magnitude of this problem may only be realized in the next few years as the daughters of women exposed to the drug reach reproductive age, the time when such abnormalities become apparent; that the situation is compounded by the relative newness of the studies associating DES with cancer and the uncertainty over the implications of recent research; and that many physicians are not yet familiar with detection and treatment techniques because the problem has been relatively recently identified. Therefore, the Legislature declares that it is imperative that programs be established to identify and diagnose persons who have been exposed to the drug diethylstilbestrol, to refer them to sources of care and treatment, and to provide an education program for physicians and other health care professionals so that exposed persons may benefit from the best possible diagnostic procedures and treatment. L.1981, c. 288, s. 1, eff. Sept. 23, 1981.
NJ Rev Stat § 26:2-114 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-114 - Definitions

26:2-114. Definitions  As used in this act: a. "Primary screening" means the initial evaluation of a person through history, physical examination and routine tests to determine the possible existence of physical changes due to diethylstilbestrol exposure; and b. "Secondary screening" means a follow-up evaluation with specialized diagnostic measures of a person identified in a primary screening as having a high probability of being diethylstilbestrol exposed, in order to confirm the existence of changes attributed to that exposure. L.1981, c. 288, s. 2, eff. Sept. 23, 1981.
NJ Rev Stat § 26:2-115 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-115 - Duties of commissioner; programs of education; secondary screening programs

26:2-115. Duties of commissioner; programs of education; secondary screening programs  The Commissioner of the Department of Health shall establish: a. A program to educate the public and health care professionals involved in primary screening about the potential hazards and afflictions which may be related to exposure to diethylstilbestrol and the symptoms and prevention of associated malignancies. The program shall include a public information campaign on diethylstilbestrol to encourage persons exposed to the drug to seek medical care for the prevention or treatment of any malignant condition. b. Secondary screening programs for diethylstilbestrol exposed persons through contract with licensed health care facilities. In contracting for the secondary screening programs, consideration shall be given to the location of the facility in relation to the concentration of population within the State and the capacity of the facility to properly conduct a secondary screening program. Each contract for a secondary screening program shall be upon such terms and conditions as the Commissioner of Health determines; but each facility shall charge each person receiving services a fee as determined by the commissioner. Where provided, all third party payors shall be accepted and utilized in securing payment for services. c. Continuing education programs for health care professionals involved in the diagnosis and treatment of diethylstilbestrol exposed persons. L.1981, c. 288, s. 3, eff. Sept. 23, 1981.
NJ Rev Stat § 26:2-116 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-116 - Registry

26:2-116. Registry  The Commissioner of the Department of Health shall maintain a registry of women who took diethylstilbestrol during pregnancy and their offspring who were exposed to diethylstilbestrol prenatally for the purpose of follow-up care and treatment of long-term problems associated with diethylstilbestrol exposure. Enrollment in the registry shall be upon a voluntary basis. L.1981, c. 288, s. 4, eff. Sept. 23, 1981.
NJ Rev Stat § 26:2-117 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-117 - Annual report

26:2-117. Annual report  The Department of Health shall make an annual report to the Legislature, through the President of the Senate, Speaker of the General Assembly and Chairmen of the Senate and Assembly Institutions, Health and Welfare Committees of its findings and recommendations concerning the effectiveness, impact and benefits derived from the programs created herein, and any recommendations for legislative changes deemed necessary. L.1981, c. 288, s. 5, eff. Sept. 23, 1981.
NJ Rev Stat § 26:2-119 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-119 - Legislative findings

26:2-119. Legislative findings  The Legislature finds that every year there are a substantial number of accidental poisonings especially among young children and that the possibility of serious injury or death which results from the ingestion of poisonous substances could be dramatically reduced by the development of a poison control and drug information program. L.1982, c. 177, s. 1, eff. Nov. 12, 1982.
NJ Rev Stat § 26:2-120 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-120 - Definitions

26:2-120. Definitions  As used in this act: a. "Commissioner" means the Commissioner of the Department of Health; b. "Program" means the poison control and drug information program established by the commissioner. L.1982, c. 177, s. 2, eff. Nov. 12, 1982.
NJ Rev Stat § 26:2-121 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-121 - Poison control and drug information program; establishment; hours of service

26:2-121. Poison control and drug information program; establishment; hours of service  The commissioner shall establish a Statewide program of poison control and drug information. Program services shall be available on a 24 hour basis to the residents of every county. L.1982, c. 177, s. 3, eff. Nov. 12, 1982.
NJ Rev Stat § 26:2-122 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-122 - Services performed

26:2-122. Services performed  The principal activity of the program shall be answering requests by telephone for poison information and making recommendations for appropriate management and treatment of poisoning exposure and overdose victims. Services of the poison control and drug information program shall also include: a. Evaluating whether treatment can be accomplished in the home setting or whether transport to an emergency treatment facility is required; b. Recommending treatment measures to appropriate personnel; c. Providing follow-up education to prevent future similar incidents; d. Providing community education programs designed to improve public awareness of poisoning and overdose problems and to educate the public regarding prevention; and e. Answering drug information questions from health professionals by providing current and accurate information relating to drugs and their therapeutic uses. L.1982, c. 177, s. 4, eff. Nov. 12, 1982.
NJ Rev Stat § 26:2-123 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-123 - Personnel utilization

26:2-123. Personnel utilization  The program shall utilize physicians, pharmacists, nurses and other necessary personnel trained in various aspects of toxicology, poison control, and drug information retrieval and analysis. L.1982, c. 177, s. 5, eff. Nov. 12, 1982.
NJ Rev Stat § 26:2-124 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-124 - Findings, declarations

26:2-124. Findings, declarations  The Legislature finds and declares that the rising incidence of heart disease, kidney disease and stroke is causing increased concern among public health officials and private practitioners who feel that it is imperative that new initiatives be developed to combat the high blood pressure which is so often associated with these life threatening conditions.  The Legislature further finds that the expansion of the comprehensive hypertension control program presently operated by the New Jersey State Department of Health with funds from federal block grants is in the best interests of the citizens of the State of New Jersey in an effort to minimize the incidence of death and disability which so often accompany uncontrolled high blood pressure.  L. 1985, c. 5, s. 1, eff. Jan. 10, 1985.
NJ Rev Stat § 26:2-125 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-125 - Definitions

26:2-125. Definitions  As used in this act:  a. "Commissioner" means the Commissioner of the Department of Health;  b. "Department" means the State Department of Health;  c. "Program" means the hypertension control program established by the commissioner.  L. 1985, c. 5, s. 2, eff. Jan. 10, 1985.
NJ Rev Stat § 26:2-126 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-126 - Expansion of hypertension control program

26:2-126. Expansion of hypertension control program  The commissioner shall expand the existing hypertension control program within the department, which shall have central authority and responsibility for the development of a system of community based high blood pressure control programs.  The commissioner shall take any action he deems necessary, including the provision of advisory and technical assistance and the development of training and educational programs, to assist qualified individuals and agencies to develop comprehensive and coordinated hypertension programs.  L. 1985, c. 5, s. 3, eff. Jan. 10, 1985.
NJ Rev Stat § 26:2-127 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-127 - Components of community program.

26:2-127 Components of community program.  4. A community based high blood pressure control program shall provide:  a. Hypertension screening;  b. Treatment referral;  c. Counseling for persons with high blood pressure as to proper diet, weight control, and appropriate care and treatment of the condition; and  d. Patient follow-up and evaluation of treatment methods.  L.1985, c.5, s.4; amended 2017, c.131, s.66.
NJ Rev Stat § 26:2-128 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-128 - Authority of commissioner.

26:2-128 Authority of commissioner.  5. The commissioner is authorized to:  a. Enter into necessary contracts and agreements with counties, municipalities and other units of government, colleges, universities, associations, agencies, corporations, and individuals for the development and expansion of community hypertension programs;  b. Gather data relative to the detection of high blood pressure and the incidence of heart disease, kidney disease and stroke;  c. Promote programs of professional education for physicians, dentists, nurses, pharmacists, and public health professionals relative to the prevention, detection and control of high blood pressure and the rehabilitation of persons with heart disease, stroke, and kidney disease which result from uncontrolled hypertension;  d. Conduct scientific investigation into the prevention, cause, detection, and control of high blood pressure;  e. Develop more effective methods for the screening, evaluation and control of hypertension; and  f. Apply for and accept any grant of money from the federal government or any other source available for the purposes of P.L.1985, c.5 (C.26:2-124 et seq.).  L.1985, c.5, s.5; amended 2017, c.131, s.67.
NJ Rev Stat § 26:2-129 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-129 - Regulations

26:2-129. Regulations  Pursuant to the "Administrative Procedure Act," P.L. 1968, c. 410 (C. 52:14B-1 et seq.), the commissioner shall promulgate any regulations necessary to effectuate the provisions of this act.  L. 1985, c. 5, s. 6, eff. Jan. 10, 1985.
NJ Rev Stat § 26:2-130 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-130 - Findings, declarations

26:2-130. Findings, declarations  The Legislature finds and declares that:  a. Exposure to lead and lead poisoning leads to morbidity, mortality, mental retardation, and learning disability in young children, the monetary and social costs of which far exceed the costs of monitoring and preventing lead poisoning.  b. The New Jersey Department of Health estimates that 44 of every 1000 children are at risk of lead poisoning and that the rate of lead poisoning among children at risk now exceeds the rate of paralytic polio at the height of the epidemic of the 1950's; however, the department has the resources to test and follow up on only 16% of the 220,000 children it estimates are at risk of lead poisoning.  c. Very few health departments have the resources to comply fully with the minimum standards of performance for local boards of health and Chapter XIII of the State Sanitary Code concerning control of lead poisoning in children due to the costs of the required testing, follow-up and abatement.  L. 1985, c. 84, s. 1, eff. March 25, 1985.
NJ Rev Stat § 26:2-131 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-131 - Definitions.

26:2-131 Definitions.  2. As used in this act:  "Child" means a person one through five years of age.  "Commissioner" means the Commissioner of Health.  "Department" means the Department of Health. "Lead poisoning" means the poisoning of the bloodstream that results from prolonged exposure to lead or lead-based substances in water, paint, building materials, or the environment, and which causes uncorrectable developmental delay and decreased mental functioning capacity in children, and in severe cases, can lead to a child's premature death.  L.1985, c.84, s.2; amended 2017, c.7, s.1.
NJ Rev Stat § 26:2-132 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-132 - Lead poisoning control program

26:2-132. Lead poisoning control program  The department, within the limits of funds appropriated for this purpose, has the responsibility for the development, implementation and coordination of a program to control lead poisoning and abate identified lead hazards by:  a. Identifying areas where there is a high risk of the presence of lead paint in a dwelling;  b. Establishing testing procedures for the detection of the presence of lead in persons and dwellings; and  c. Stimulating professional and public education concerning the need to test, detect and control lead poisoning and to abate identified lead hazards.  L. 1985, c. 84, s. 3, eff. March 25, 1985.
NJ Rev Stat § 26:2-134 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-134 - Comprehensive plan

26:2-134. Comprehensive plan  Within six months of the effective date of this act, the commissioner shall prepare a comprehensive plan to control lead poisoning in the State. The commissioner shall submit the plan to the Governor and the Legislature.  L. 1985, c. 84, s. 5, eff. March 25, 1985.
NJ Rev Stat § 26:2-135 (2021)
2021 New Jersey Revised Statutes|Title 26 - Health and Vital Statistics|Section 26:2-135 - Annual report

26:2-135. Annual report  6. The commissioner shall issue an annual report to the Governor and the Legislature by October 1 of each year. The report shall include a summary of the lead poisoning testing and abatement program activities in the State during the preceding fiscal year and any recommendations or suggestions for legislative consideration. This report shall be made available to local and State agencies involved with case management and lead abatement, and to interested members of the public. L.1985, c.84, s.6; amended 1995,c.328,s.7.